Navigation Links
Positive Results From Avanafil Post-Prostatectomy Study Featured at Cancer Survivorship Meeting
Date:6/17/2011

DA relating to matters raised in the FDA's QNEXA CRL; the timing and results of the retrospective observational study of fetal outcomes in infants born to mothers exposed to topiramate during pregnancy; the FDA's interpretation of and agreement with the information VIVUS submitted and may submit relating to teratogenicity and cardiovascular safety; the FDA's interpretation of the data from our SEQUEL study, or OB-305; the FDA's requests, if any, to conduct additional prospective studies or retrospective observational studies or to provide further analysis of clinical trial data; the review and questions from the EMA and CHMP on the QNEXA MAA; substantial competition; the impact on future sales based on specific indication and contraindications contained in the label and the extent of the Risk Evaluation and Mitigation Strategies program; uncertainties of litigation and intellectual property and patent protection; reliance on sole-source suppliers; limited sales and marketing resources and dependence upon third parties; risks related to the development of innovative products; risks related to the failure to obtain FDA or foreign authority clearances or approval; noncompliance with FDA or foreign regulations; and our dependence on the performance of our collaborative partners. As with any pharmaceutical in development, there are significant risks in the development, the regulatory approval, and commercialization of new products. There are no guarantees that our response to the FDA's CRL on QNEXA or the results of the retrospective observational study of fetal outcomes in infants born to mothers exposed to topiramate during pregnancy and subsequent meetings and communications will be sufficient to satisfy the FDA's safety concerns, that the FDA will not require us to conduct any additional  prospective studies or retrospective observational studies, or that any product will receive regulatory approval for any indication or prove to be commercially successful. VIVU
'/>"/>
SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Neurelis Announces Positive Results from Phase 1 Pharmacokinetic Study of NRL-01 (intranasal diazepam)
2. Dong-A PharmTech Co., Ltd. and Dr. Falk Pharma GmbH Announce Positive Data in Portal Hypertension With Udenafil
3. BioSpecifics Announces Positive XIAPEX® Data Presented at XVI Annual Federation of European Societies for Surgery of the Hand Congress
4. Tigris Pharmaceuticals Initiates Randomized Phase 2 Study of AFP-464 in ER-Positive Breast Cancer Patients
5. Boehringer Ingelheim to present new data at ASCO annual meeting regarding its investigational compound afatinib in EGFR-mutation positive patients with advanced NSCLC
6. Sinovac Reports Positive Phase I Clinical Trial Results for EV71 Vaccine Candidate Against Hand, Foot & Mouth Disease(HFMD)
7. KemPharm, Inc. Announces Positive Results from Phase 1 Trial of KP201 for Pain
8. Amgen Receives CHMP Positive Opinion for XGEVA™ (Denosumab) in the European Union
9. Positive Results from Long-Term Phase 3 Study of Avanafil Featured at American Urological Association Annual Meeting
10. Positive Results Reported for Phase II Randomized Double-Blind Clinical Trial for the Treatment of Drug-Resistant Epilepsy Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
11. Reportlinker Adds Advanced Lung Cancer with EGFR Mutation Positive Adenocarcinoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Perrigo Company plc ("Perrigo") (NYSE: PRGO ... (NASDAQ: MYL ) shareholder vote regarding its planned ... of Mylan,s offer to Perrigo shareholders have always been, ... careful reflection of the value available to Perrigo shareholders, ... Mylan has allowed its shareholders to consider," said ...
(Date:8/28/2015)... The report "Eubiotics Market by Type (Probiotics, Prebiotics, ... Aquaculture), & by Region ( North America , ... and Rest of the World) - Global Trends and Forecast ... was valued at USD 4.62 Billion in 2014 and is ... CAGR of 7.4% from 2015 to 2020. ...
(Date:8/27/2015)... Mass. , Aug. 27, 2015  A ... the KSSTA Knee Journal, compared the Arthrosurface HemiCAP® ... Arthroplasty design, versus an "onlay" design implant for ... similar improvements in function and pain scores, none ... progression of osteoarthritis (OA). However, 53% of the ...
Breaking Medicine Technology:Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3
... fundamental traits of a,tumor – how it avoids ... according to researchers from the,University of Southern California. ... cancers, indicate that,a technique for determining a tumor’s ... cancers. , ,In the July 1 issue ...
... - Nymox,Pharmaceutical Corporation (NASDAQ: NYMX) today announced ... of NX-1207 for,benign prostatic hyperplasia (BPH) will ... the American Urological Association Meeting in,Boston in ... clinical,research investigators from U.S. clinical trials of ...
Cached Medicine Technology:Researchers Discover Method for Identifying How Cancer Evades the,Immune System 2Researchers Discover Method for Identifying How Cancer Evades the,Immune System 3Clinical Data From Nymox BPH Drug To Be Presented at American,Urological Association Meeting 2
(Date:8/28/2015)... IL (PRWEB) , ... August 28, 2015 , ... With ... benefit concert returned for the second year to the Adams County Fairgrounds in Mendon, ... was held to raise money to support music education in the underfunded school districts ...
(Date:8/28/2015)... ... ... The 6th Annual Survivor in the City, Chicago silent auction and cocktail ... its cadre of widespread support—an official letter of support and gratitude from the Mayor ... and the University of Illinois at Chicago’s Department of Neurosurgery, the Brain Aneurysm Foundation ...
(Date:8/28/2015)... ... ... Frequentz ” was featured on NewsWatch as part of its monthly AppWatch, which takes ... and Windows. Joe Toohey, the host of AppWatch and technology expert, conducted the app ... from beginning to end. , Businesses benefit greatly from having the ability to track ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... Veterans Award, honoring military veterans leading in business. Mr. Troy Mizell, Chairman ... , The inaugural Nashville Business Journal's 2015 Veterans Awards will recognize Nashville military ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Quatela Center for Plastic Surgery ... first and only nonsurgical product approved by the Food and Drug Administration to eliminate ... and Dr. William Koenig are among the premier cosmetic surgeons in Rochester ...
Breaking Medicine News(10 mins):Health News:Best Drug Rehabilitation Interviews Country-Rock Duo Highway Run at the 2015 "Music With A Mission" Benefit Concert 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 3Health News:Track Product Movement from Beginning to End with Frequentz 2Health News:MyGenetx Board Member Receives Veterans Award 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 3
... closed, American cardiologists say , , WEDNESDAY, July 2 (HealthDay ... to adrenaline did not improve survival among people who ... American cardiologists said the finding does not rule out ... report comes from a group, primarily French, that several ...
... 2 Hanger Orthopedic,Group, Inc. (NYSE: HGR ... Poor,s,Rating Services revised its outlook for Hanger Orthopedic ... Hanger,s corporate credit,rating at "B." "The outlook revision ... an improved financial risk profile," said,Standard & Poor,s ...
... medicine specialist, John Albright, MD, will join three other physicians as ... Fame inductee. , ... Orlando, Florida (PRWEB) July 2, ... will join three other physicians as a 2008 American Orthopaedic ...
... Ambulatory Services of,America, Inc. announced the acquisition of ... from Affiliated Hospitals Dialysis Center.,Affiliated Hospitals Dialysis Center ... and St. John,s Mercy Health System. Prior,to the ... 300 patients,through the three outpatient dialysis centers and ...
... Larry Minnix, President & CEO, American Association of,Homes ... of the Medicare Therapy,Caps Exceptions Process, WASHINGTON, ... Minnix, President & CEO, American Association of Homes ... the Medicare Therapy Caps,Exceptions Process:, "Medicare beneficiaries ...
... Ambulatory Services of,America, Inc. announced the formation of ... to provide outpatient radiation oncology services. ROSA,of North ... Radiation,Oncology Services of America, and some of the ... North Dallas will own and operate Northpoint,Cancer Center ...
Cached Medicine News:Health News:Two-Drug Treatment Didn't Improve Cardiac Arrest Survival Rates 2Health News:Two-Drug Treatment Didn't Improve Cardiac Arrest Survival Rates 3Health News:Hanger Orthopedic Group, Inc. Receives Positive Outlook from Standard & Poor's Rating Services 2Health News:Renowned Iowa Orthopaedic Surgeon, John Albright, MD, Inducted into Sports Medicine Hall of Fame 2Health News:Renowned Iowa Orthopaedic Surgeon, John Albright, MD, Inducted into Sports Medicine Hall of Fame 3Health News:Ambulatory Services of America, Inc. Announces the Acquisition of Dialysis Operations in St. Louis, Missouri 2Health News:AAHSA Statement: Therapy Caps Ration Care 2Health News:Ambulatory Services of America, Inc. Announces Joint Venture to Operate Radiation Oncology Facility in Dallas, Texas 2
3 mm, 130 degree upwards cutting, detachable....
Aaron 950 is a high frequency desiccator with cut....
Sabre 180 is a powerful niche generator....
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
Medicine Products: